Design Data introduces MySerialS: advancing the analysis of pharmaceutical serialization alerts
- 2 days ago
- 3 min read
MySerialS, a new approach to identifying truly atypical serialisation alerts
The implementation of pharmaceutical serialization across Europe has significantly strengthened the traceability of medicines within the supply chain.
Today, individual medicine packs can be verified from the manufacturing site through to dispensing to the patient.
This represents a major step forward in the fight against falsified medicines and in safeguarding the integrity of pharmaceutical distribution networks.
At the same time, the widespread adoption of serialization systems has introduced a new operational challenge for National Medicines Verification Organisations (NMVOs) and pharmaceutical companies: the effective analysis of large volumes of serialization alerts.
To address this evolving challenge, Design Data is introducing MySerialS, a new analytical solution designed to support organisations in identifying unusual patterns within serialization alert data and prioritising investigations more effectively.
A growing challenge for serialization alert management
Since the introduction of the Falsified Medicines Directive (FMD) and related verification systems, a significant amount of operational data has been generated across the pharmaceutical distribution network.
Every verification event within the supply chain has the potential to trigger an alert. And in certain circumstances, a single operational issue or data inconsistency can lead to thousands of alerts within a short period of time.
For NMVOs and pharmaceutical companies, the key challenge is therefore not the availability of data, but the ability to determine quickly:
which alerts correspond to routine operational issues
which situations require deeper investigation
which patterns may indicate potential risks within the supply chain
Limitations of traditional analytical approaches
In many organisations, the analysis of serialization alerts still relies on a combination of:
data extracts
spreadsheet-based analysis
ad hoc investigations
operational expertise
While these approaches allow teams to review the data, they can become increasingly difficult to manage as alert volumes grow.
As a result, potentially relevant signals may remain difficult to detect within large data sets.
The evolution of serialization data analytics
Over time, analytical tools have begun to bring greater structure to the investigation of serialization alerts.
Platforms such as Serial BI already enable organisations to explore serialization data more effectively and conduct structured investigations across multiple analytical dimensions.
However, the growing volume and complexity of data now require an additional level of analytical capability.
Rather than relying solely on manual exploration, it is increasingly possible to identify statistically unusual patterns within alert data.
MySerialS: supporting the identification of atypical alerts
With MySerialS, Design Data introduces a new analytical layer designed to support the identification of atypical behaviours within serialization data.
The solution combines advanced statistical models with artificial intelligence techniques in order to detect unusual variations across large alert datasets.
The objective is to support investigation teams by highlighting situations that may warrant closer attention.
In practical terms, MySerialS helps organisations to:
identify statistically significant deviations within alert data
detect weak signals that may otherwise remain unnoticed
focus investigative efforts on potentially relevant cases
READ ALSO
Towards more advanced analysis of serialization data
The introduction of analytical solutions such as MySerialS reflects a broader evolution in how serialization data can be utilised.
Alert management is progressively shifting from manual data exploration towards augmented analytical approaches capable of surfacing unusual behaviours within complex datasets.
For organisations involved in protecting the pharmaceutical supply chain, these developments represent an important opportunity to strengthen anomaly detection and improve the efficiency of investigative processes.
Conclusion
Serialization has considerably improved the traceability and security of medicines across the pharmaceutical supply chain.
At the same time, the resulting increase in data volumes requires new analytical approaches to ensure that relevant signals can be identified efficiently.
With the introduction of MySerialS, Design Data contributes to this evolution by providing an analytical capability designed to support the identification and prioritisation of atypical serialization alerts.
Organisations interested in understanding how MySerialS can support the analysis of serialization alerts are invited to explore the solution in more detail.
Design Data Consulting, Consulting & Intelligent Management Dashboards to Simplify Decision-Making.
